INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

MacLeod Alan Robert reported ADRX

Chief Scientific Officer · ADARx Pharmaceuticals, Inc. · ADARx Pharmaceuticals, Inc. — Employee Stock Option (right to buy)

Side
A
Value
—
Shares
170.7K
Price
—
Executed
Sep 24, 2026
Disclosed
Sep 28, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Sep 24 executedSep 28, 2026 disclosed

ADRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ADRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    ZN
    Zhu Rui (NMN)Chief Technology Officer
    ADRXADARx Pharmaceuticals, Inc.
    Grant or award
    		A—
    512.1K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    9
    FR
    Fisk RyanCFO and CBO
    ADRXADARx Pharmaceuticals, Inc.
    Grant or award
    		A—
    170.7K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AW
    Ackles Robert WilliamChief People Officer
    ADRXADARx Pharmaceuticals, Inc.
    Grant or award
    		A—
    85.3K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    9
    LZ
    Li ZhenDirector, President and CEO, 10% Owner
    ADRXADARx Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.02M sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002154450-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 24, 2026
    Published
    Sep 28, 2026
    Ingested by INSIDER
    Nov 5, 02:14 UTC
    Last re-read
    Nov 5, 02:14 UTC

    Extracted facts

    Filer
    MacLeod Alan Robert
    Role
    Chief Scientific Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    ADARx Pharmaceuticals, Inc. — Employee Stock Option (right to buy)
    Ticker
    ADRX
    Shares
    170.7K
    Price per share
    $0
    Execution date (reported)
    Sep 24, 2026
    Owned after transaction
    170.7K shares
    Days from execution to publication
    4

    What this establishes

    MacLeod Alan Robert filed this Form 4 reporting a grant or award of ADRX on Sep 24, 2026. It became public on Sep 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Scientific Officer
    MacLeod Alan Robertcik:0002154450
    Issuer
    ADARx Pharmaceuticals, Inc.cik:0001802369

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.